In HHT, anti-VEGF treatment has been found to restore tissue TSP-1 and ANG-2 levels and improve the microvascular phenotype [37], as well as prevent the formation of AVMs in mouse models [38]. Here, VEGFA is linked to hereditary hemorrhagic telangiectasia.